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1. Introduction 
Hepatocellular carcinoma is the fifth most common neoplasm in the World and the third 
most common cause of cancer related death (1). It accounts for 7.4% of all cancers in males 
and 3.2% of all cancers in females (2). 
An early diagnosis of HCC is required for the institution of treatments considered to be 
curative. On this basis, screening of each patient with liver cirrhosis should be performed by 
ultrasound and by measurements of serum alphafetoprotein (AFP) at 6-months interval 
(3).There are different methods for active management of HCC, many factors related to the 
tumour itself and to the patient may make a tumour unresectable (4). 
Radio frequency ablation (RFA) is the most common therapy used in patients not suitable 
for resection. In RFA, an electric current that is passed into the tumour tissue via an 
electrode tip results in heat generation and coagulative necrosis (5). The advantage of radio 
frequency is the small number of sessions needed to obtain tumour necrosis (6). The aim of 
the present study was to evaluate the radiofrequency thermal ablation as a method for 
treatment of hepatocellular carcinoma.  
2. Patients and methods  
This retrospective study was carried out at Ain-Shams University Hospital (Hepatoma unit),  
including patients attending the unit during the period between January 2004 to January 2006.  
All patients were subjected to the following: 
1. Full history with special emphasis on the newly developed persistent right upper 
abdominal pain, and unexplained hepatic decompensation 
2. Full clinical examination including: 
A. General examination : with stress on signs of liver cell failure including  jaundice,  
flapping tremors, plamar erythema,  lower limb edema  
B. Local abdominal examination: with special stress on the presence of signs 
suggestive of hepatic malignancy e.g. hepatic mass and hepatic bruit.  
3. Laboratory investigations: 
Complete blood picture, liver profile, coagulation profile, hepatitis markers, serum blood 
glucose, and renal function tests. 
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Tumour markers including AFP, CA and CEA antigens for exclusion of metastasis from the 
GIT. 
4. Radiological evaluation: 
a. Pelviabdominal U.S. examination; 
To evaluate the number, size, and location of the hepatic focal lesions, and to exclude portal 
vein thrombosis, hepatic vein obstruction, porta-hepatis or coeliac lymph node enlargement, 
and ascites. 
b. Abdominal tri-phasic spiral C.T. scan to accurately evaluate the pattern of 
enhancement of the focal lesions, vascular or biliary invasion specially portal vein 
thombosis. The suggestive criteria for HCC were considered present when there 
was enhancement of the focal lesion with the I.V dye so it appeared hyperdense in 
the arterial phase, then it became hypodense in both portovenous and delayed 
phases due to the wash out of the dye from the focal lesion. 
The above mentioned findings were used as a reference for evaluation of the response after 
ablation. 
c. Chest x-ray to exclude pulmonary metastases. 
Patients were stratified according to Child-Pugh Classification (7) 
Diagnosis of HCC was done based on the presence of at least 2 of 3 of the following criteria: 
1. Hepatic focal lesion detected by abdominal ultrasound and has positive criteria of 
HCC in spiral CT scan. 
2. Alphafetoprotein >200ng/ml (8). 
3. Guided biopsy from the focal lesion was performed when one of the above 
mentioned criteria was missed. 
Seventy four patients with proved hepatocellular carcinoma were selected for treatment by 
ultrasound-guided percutaneous radiofrequency ablation according the following inclusion 
criteria; 
1. Patients with unresectable hepatic malignancies. 
2. No   evidence of extra-hepatic disease.  
3. Absence of vascular or biliary invasion. 
4. Presence of not more than 2 focal lesions, each is less than 5cm. 
5. Child-Pugh's class A, and B. 
6. Tumours in position where the electrode can be inserted and  held safely. 
Absolute contra-indications include: 
- Sever debilitation. 
- Active infection. 
- Uncorrectable coagulopathy. 
- Pregnancy. 
After imaging study, patients were divided into 2 groups according to the number of focal 
lesions: 
Group I: patients with single hepatic focal lesion. 
Group II: patients with 2 hepatic focal lesions. 
Premaneuver assessment: Patients were admitted to Tropical Medicine Department for 
Premaneuver assessment including cardiac and chest examination, ECG, blood pressure and 
blood glucose level evaluation. Ascites in ascetic patients was also controlled by diuretics 
and tapping if needed. 
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Radiofrequency ablation systems: 
The two machines used in this study were:  
a. The RITA model 1500RF. 
b. RF 2000 system, produced by the RadioTherapeutics Corporation. 
Radiofrequency ablation technique: 
Patients with one focal lesion were treated in single RFA setting while patients with 2 focal 
lesions were treated either in single or over 2 settings separated by one week, so 80 sessions 
were done for 80 lesions. Percutaneous radiofrequency ablation was used to treat a total of 
80 lesions which were detected by U.S and C.T in the 74 patients. 
Pre-ablation assessment: 
General assessment:     
Medical history was revised and the laboratory test results were checked, and the ECG was 
interpreted with chest and cardiac examination. A peripheral I.V. line was started, and the 
patient was monitored for blood pressure, pulse, respiratory rate, and the peripheral 
oxygenation. 
Ultrasound approach assessment:   
Percutaneous RFA was performed with real- time US guidance by using 3.5 MHz convex 
probe. Pre-ablation US assessment was performed to re-evaluate the number and size of the 
tumours, their relationship to surrounding structures as blood vessels, bile ducts, gall 
bladder, diaphragm, and bowel, and to determine if a safe and adequate approach exists. 
The most appropriate approach for electrode insertion was detected. For tumours located in 
the right lobe, an intercostal approach with the patient in the left lateral decubitus position 
generally was preferred. For tumours located in the left lobe, a subcostal approach was used 
most often. The procedure was done in the interventional radiology unit (a special sterilized 
unit) containing the ultrasound machine (Siemens, Toshiba), the services of general 
anesthesia, the radiofrequency system, and a mobile sterile table (for sterile patients and 
doctors' gowns, antiseptics, syringes, IV fluid, medications, and gauze). The grounding 
pads, representing the dispersive electrode, were placed on the patient's thighs and properly 
connected to the generator. The system was tested to be sure working. 
Anesthesia and medications: 
Local anesthesia was performed from the entry site on the skin to the liver capsule along the 
needle track with 10 ml of 2% xylocaine. Skin was pricked it has small sterile lancet. Most of 
the patients undergone RFA were treated under general intravenous anesthesia.  
Needle electrode placement: 
The needle electrode was introduced into the liver through the skin incision under U.S. or 
C.T. guidance. After verifying the positioning of the needle electrode, the multiple arrays 
were deployed and the needle electrode was connected to the RF generator. 
Treatment strategy: 
The objective in treating the tumours was to ablate the entire tumour as well as at least 1 cm-
tumour- free margin of normal liver. 
The deepest ablations were performed before the superficial ones to minimize the possibility 
of those microbubbles might obscure visualization of the deepest portions of the tumour 
and thus prevent completion of the ablation. The hilar portion of the tumour was ablated 
initially in order to destroy the inflow of blood supplying the tumour.  
The needle electrode was first placed at the most posterior margin and at one side of the 
tumour, then to the other side. Multiple overlapping ablations were then sequentially 
performed progressing superficially and then laterally at 2-2.5 cm intervals within the 
tumour until the tumour and 1 cm-free margin had been successfully ablated. 
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As we start RFA session a hyper-echoic focus developed around the un-insulated portion of 
the electrode. This was attributed to tissue vaporization and cavitations. The area of 
echogenicity was round; most often progressively increased in size over the course of 
ablation and generally enveloped the entire tumour with variable extensions in the 
surrounding liver by the end of the treatment. 
In some cases, the hyper-echoic focus did not develop progressively but appeared rather 
suddenly and was accompanied with an audible popping sound emanating from the liver. 
Cool down: 
When the timer runs out the generator well automatically goes into Cool Down mode for 30 
seconds (5 minutes on the generator display), when the Cool Down is complete, the 
temperatures from all leads must be above 70°C, if not we continue ablation for another 5 
minutes at target temperature, or we can rotate the device 45 degree to check temperature 
and continue ablation if still temp below 70°C. 
Track ablation: 
In most of our cases we ablate the tract before removal of the needle. 
Post Ablation care: 
IV antiemetic was given if needed, Strong IV analgesics were given to pain as pethidine 
hydrochloride 50 mg or tramadol. All patients were observed clinically for 2-3 hours in the 
Radiology department to detect any acute complications and to start IV fluid. Prophylactic 
antibiotic were started, amoxicillin-clavulanic acid (augmentin) or ceftazidine (fortum), and 
metronidazole (flagyl), and continued for 3 days. 
Post treatment follow up 
All patients underwent dynamic CT scan 1 month after completion of the therapy to detect 
any residual enhancing tumour tissue. If any area suspicious for viable tissue was detected, 
the patient was retreated by RFA of this area. Then, follow up CT was done after 3 months, 
then every 6 months to detect any local recurrence in the ablated tumour or de novo lesion. 
Alphafetoprotein level was assessed accompanying performance of CT. After 1 month if its 
level was still elevated, it indicated incomplete tumour ablation. Follow up after complete 
ablation was to detect any minor elevations which detect recurrence. 
3. Results 
Table 1 shows the demographic and clinical data of the studied patients.  
Thirty one patients had their AFP level above the diagnostic value (200ng/ml), while the 
remaining 43 patients had AFP level less than 200. The (M ± SD) of serum alphafetoprotein 
level (AFP) was 12086 ± 7345 ng/ml and ranged between 1.8 ng/ml and 350000 ng/ml, as 
shown in table 2 which illustrates also the remaining liver profile. All patients were positive 
for hepatitis C antibody and negative for HbsAg. HbcAb was detected in 7 patients.  
Abdominal ultrasound findings are shown in table 3. The findings of spiral CT in this study 
were similar to that of abdominal ultrasound as regard the number, site and diameter of the 
hepatic focal lesion. In this study, the spiral CT criteria suggestive for HCC were present in 
63 cases (85.1%) and absent in 14 cases (14.9%) (they were proved to be HCC by biopsy. 
Forty two Patients (56.8%) were within Child Pugh class A and 32 patients (43.2%) were within 
Child Pugh class B (patients in Child class B were with minimal and controlled ascites).   
Tumour character: The seventy four patients included in the study were divided into 2 
groups according to the number of focal lesions in each patient. Sixty eight patients form 
group I and had only one focal lesion (68 lesions) and the maximum diameter of the 
tumours was 3 cm or less in 42 patients and was from 3-5 cm in 26 patients. Group II formed 
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of patients with 2 hepatic focal lesions and included 6 patients with 12 focal lesions. In 
group II, the maximum diameter of the tumours was 3 cm or less in 6 lesions of 6 patients 
and was from 3-5 cm in another 6 lesions of the same 6 patients (Table 3). 
 
Mean 55.5 years 
Age 
± SD 7.8 years 
Gender No. of the patient % 
Males  57 77% 
Females  17 23% 
Symptoms 
Rt. Hypochondrial pain 58 78.3% 
Loss of appetite 25 33.8% 
Itching  9 12.2% 
Loss of weight 21 28.4% 
Jaundice  23 31.1% 
Ascites  11 14.9% 
Fever  10 13.5% 
Easy fatigability  35 47.3% 
Risk factors for infection with hepatitis viruses. 
Schistosomasis & treatment 
with tartar emetic 
40 54.1% 
Blood transfusion 28 37.8% 
Surgical operations 38 51.4% 
Dental procedures 24 32.4% 
General Examination 
Pallor 6 8.1% 
Jaundice 30 40.5% 
Flapping Tremors 11 14.8% 
Palmar erythema 25 33.8% 
Lower Limb edema 36 48.6% 
Abdominal Examination 
Palpable liver  44 59.4% 
Tender liver  0 0% 
Ascites  10 13.5% 
Splenomegaly  13 17.6 
Table 1. Demographic and clinical data of the studied patients. 
 
 Mean ± SD 
AFP 12086 7345 
ALT ( IU/L)  66.8 32.5 
AST (IU/L)  94.8 36.4 
Albumin (gm/dL)  2.9 0.4 
Bilirubin (mg/dL)  1.7 0.6 
Table 2. Laboratory findings of the studied patients. 
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GI (n=68), 68 
lesions 
GII (n=6), 
12lesions 
No. of patients 42 6 
Lesion <3cm 
No. of lesions 42 6 
No. of patients 26 6 
Lesion 3-5cm 
No. of lesions 26 6 
Table 3. Tumour character in the studied patients: 
Results of treatment with Radiofrequency ablation:  
During the first follow up done one month after ablation, 68 patients (91.9%) showed 
complete ablation with no evidence of residual and 6 patients (8.1 %) showed  incomplete 
ablation  [ 3 patients in group I and 3 patients in group II, all of them with lesion diameter  
3-5cm] (Table 4)  
 
Group I (68 patients, 68 lesions) Group II (6 patients, 12 lesions) 
<3cm 3-5cm <3cm 3-5cm 
Number 
of 
patients
Number 
of  
lesions 
Number 
of 
patients
Number 
of  
lesions 
Number 
of 
patients
Number 
of  
lesions 
Number 
of 
patients 
Number 
of  
lesions 
 
42 42 26 26 6 6 6 6 
Complete 
ablation 
42 
(100%) 
42 
(100%) 
23 
(88.4%)
23 
(88.4%)
6 (100%) 6 (100%) 3 (50%) 3 (50%) 
Partial 
ablation 
0   (0%)
0       
(0%) 
3 
(11.5%)
3 
(11.5%)
0      
(0%) 
0    (0%) 3 (50%) 3 (50%) 
Table 4. Results of RFA after one month 
During the second follow up done after 3 months, 71 patients (95.9 %) had no evidence of 
local or distant recurrence. Local recurrence occurred in 3 patients in group I (4.1%). 
During the third follow up done after 6 months, 70 patients (94.6%) showed no evidence of 
recurrence and 4 patients (5.4%) [2 patients in group I and 2 patients in group II] had a new 
focal lesion at distant sites of the liver.  
During the fourth follow up done after 12 months, 72 patients (97.3%) showed no evidence 
of recurrence and 2 patients (2.7%) had a new focal lesion at other sites of the liver both were 
in group II (Table 5). 
 
Group I (n=68 patients) Group II (n=6 patients) 
 Local 
recurrence 
Distant 
recurrence 
Local 
recurrence 
Distant 
recurrence 
3 months 3 0 0 0 
6 months 0 2 0 2 
12 months 0 0 0 2 
Table 5. Results of 3, 6 and 12 months follow up after RFA 
The residual of the tumour was managed by a second session of RFA. All local or distant 
recurrences were managed by a second RFA session when in suitable site except in one 
patients was near a biliary radicle, so managed with intralesional ethanol injection. 
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*Follow up of Laboratory investigation:  
As regards the liver enzymes, ALT was significantly elevated one month after RFA sessions 
(92.8 ± 36.4 IU/L) more than before ablation (P < 0.01), the same was noticed for AST which 
was also significantly higher (98 ±32.5 IU/L ) (P<0.01). During the second follow up done 
after 3 months, ALT and AST returned to base line levels. 
Three months after RFA, serum albumin was higher and ranged between 2.8-4.5 gm/dl 
with (M ± SD: 0.2± 0.4gm/dl), serum bilirubin was lower and  ranged between 0.6-1.9 
mg/dl with (M ± SD: 0.9±0.4gm/dL). 
Before treatment with RFA serum A FP values were elevated (>200ng/mL) in 31patients 
(41.8%). Table 6 shows the patients with AFP level>200 during the follow up period after 
ablation. 
 
AFP>200ng/ml  
No. of patients % 
Before RFA 31 41.8% 
One month after RFA 17 22.9% 
After three months 9 12.2% 
After 6 months 5 6.7% 
After 12 months 3 4.1% 
Table 6. Patients with AFP>200ng/ml before and after RFA. 
There were no fatal complications related to RFA treatment. Nearly all the patients 
experienced post-ablation right hypochondrial pain that was controlled by analgesics, and 
nausea (70 patients, 94.5%), which was controlled by antiemetics Also, nearly all 
experienced post – ablation pyrexia for 1-3 days, which was controlled by antipyretics. 
Pneumonia occurred in only one patient (1.3%) and ascites developed in 2 patients (2.7%) . 
Only one patient developed pneumothorax due to ablation of Sub-diaphragmatic tumour 
and another 2 patients developed ascites within the first week post ablation.  
At the end of this study after one year, survival analysis was evaluated. Two patients (2.7%) 
died as result of advanced liver disease. So, overall survival rate was 97.2% (72/74 patients).  
Disease free survival rate was 79.7% as thirteen patients (17.6%) survived with recurrent 
HCC and fifty nine patients (79.7%) were disease free over the follow up period (Table 7).  
 
Survival status Number of patients % 
Disease free survival patients 59 79.7% 
Survived with recurrent disease 13 17.6 % 
Died patients 2 2.7 % 
Total number 74 100% 
Table 7. Survival rates evaluation in the study 
4. Discussion 
Hepatocellular carcinoma (HCC) is the fifth most common neoplasm in the world and the 
third most common cause of cancer related death. Currently, it is the leading cause of death 
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among cirrhotic patients (1). The studies carried out on hepatocellular carcinoma are scarce 
in Egypt. Nevertheless, they presumed an upward trend for HCC among chronic liver 
disease (CLD) patients (9). 
For the last two decades several minimally invasive interventional ablative techniques 
aiming at providing local destruction of the tumour have been developed.  Radiofrequency 
thermal ablation (RFA) is a more recently developed for local tissue ablation.  
This retrospective study was performed on 74 patients with hepatocellular carcinoma 
attending Hepatoma unit of Ain Shams University during the period between January 2004 
and January 2006. 
In this study, it was found that the number of male patients was higher than females (57 
male and 17 females) with ratio 3.4:1 and this agrees with Sherlock and Dooley 2002 who 
reported that in patients with HCC males exceed females in a ratio of 4-6:1(2). Also, 
Marrero, 2003 stated that male population both black and white is primarily affected (10). 
The newly developed persistent right hypochondrial dull aching pain was the most 
common complaint of patients included in this study (78.3%). This is a very important 
finding and it meets the finding of Hillebrand and Sandowski, 2000 who found that 
although the percentage of patients having specific signs and symptoms differs in high-
incidence and low incidence areas of HCC, the most common complaint remains abdominal 
pain (4). Pain is frequent but rarely severe and is felt as a non-specific, continuous dull ache 
in the epigastrium, right upper quadrant, or the back. Severe pain is due to perihepatitis or 
involvement of the diaphragm (2). 
The etiology of chronic liver disease in patients of the study was hepatitis viruses’ infection 
(HBV and/or HCV). In Egypt, HCV seroprevalence is 55% among children who had 
received blood transfusions and 67% among patients on renal dialysis, and is 10% among 
sexually transmitted disease patients (11). 
In this study, 67 patients (90.5%) were positive for HCV antibody. The prevalence of HCV 
antibody positive patient with HCC was found to be 62% in Spain, 65% in Italy, 29% in 
South Africa and 29% in United States (12).  
In this study all patients were negative for HBsAg but when HBcAb IgG was assessed 
(which indicates past infection with HBV), it was found that HBcAb IgG was positive in 7 
patients (9.5%) of the study. these results agree also with El-Zayadi et al., 2001 who placed 
Egypt among the countries of intermediate prevalence for HBV as HBV accounts for 10-30% 
of CLD and HBsAg carriage was reported in 5.6% (9). 
Owing to the use of ultrasound surveillance in patients with hepatic cirrhosis, HCC is 
diagnosed in an increasing number of patients at an early asymptomatic stage (13). Patients 
with early stage HCC should be considered for any of the available curative treatment 
options including surgical resection, liver transplantation and percutaneous techniques of 
tumour ablation (14). In the recent decade, ultrasound guided percutaneous ethanol injection 
(PEI), as a local therapy for hepatic tumours, has gradually been replaced by intraoperative 
or percutaneous RFA (15). RFA was considered by many authors as superior to other existing 
loco regional therapies as percutaneous ethanol injection (PEI), transarterial 
chemoembolization (TACE) and microwave ablation (16). 
In the present studying RFA was used to treat 80 tumours in 74 patients. The 80 tumours 
included 48 tumours (60%) less than 3 cm in diameter and 32 tumours (40%) 3-5cm in 
diameter. 
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Generally, a single ablation of 5cm in diameter could successfully destroy liver tumour 
smaller than 3cm plus the safety margin of 0.5-1cm (17).  In the present study, after one month 
of RFA , all the 48 tumours (100%) less than 3cm in diameter shoed complete ablation while 
26/32 (81.3%) of tumours between 3-5cm showed complete ablation and 6 tumours (18.7%) 
showed residual viable tumour tissue (i.e. partial or incomplete ablation). In a study by 
Chen et al. 2005 (17), cases with tumours larger than 3.5cm in diameter accounted for 61.8% 
(207/335 cases) of their study population, and they got 85.9% response rate (178/207 cases), 
results nearly similar to the results of the present study. The whole complete response rate 
for all tumours was 92.5% (74/80 tumours), the 6 incompletely ablated tumours (7.5%) were 
larger than 3cm in diameter. These results are also near the results of Chen et al. 2005 who 
reported 94.8% (723/763 tumours) total ablation rate of the initial RFA. Of the 40 
incompletely ablated tumours, 33 (82.5%) were larger than 3.5cm (17). These data support the 
fact that the most important factor for efficacy of RFA is the size of the tumour and the RFA 
could successfully ablate smaller liver tumours. Sala et al 2004 (18) supports this by the 
results of their study as they reported initial complete response of 96% in tumours 2cm or 
smaller and this figure decreased to almost 50% in multinodular or large HCC and this 
figure is similar to that reported by most referral groups (19).  
All cohort studies assessing percutaneous ablation report the appearance of viable tumour 
tissue within the treated nodule or its vicinity after initial complete response (20). This was 
met in our study as, three months after ablation local recurrence occurred in three patients 
in group I.  Six months after ablation, 4 patients (2 in each group) showed distant recurrence 
and 2 other patients in group II showed another distant recurrence after one year. This event 
is heterogeneously defined (distance from the main nodule, location in the same segment) 
and named (21). This is usually termed local recurrence or local tumour progression (21).  Sala 
et al 2004 reported local tumour progression in 76 patients in their series of 192 patients after 
initial complete response with a 1, 3, 5 years probability of 26%, 56%, and 74% respectively. 
Most were detected early in the follow up, but 34% were registered at 2 years and 13% were 
detected beyond 3 years (18). Unfortunately, results of our study can not be compared with 
results of Sala et al 2004 as the follow up period here is only one year. 
Even tumours 2cm or smaller can present with late failure and studies in resected tumours 
explain this: one third of tumours with 3cm or smaller present microscopic vascular 
invasion or satellites, which will almost likely not be affected by ablation and emerge as 
failure early or late during follow up (22). 
At the end of the follow up period in our study (1year), the overall survival rate was 97.3% 
i.e. 72 patients alive and 2 patients died due to disease progression. Fifty nine patients 
(79.7%) represented the disease free survival while 13 patients (17.5%) lived with either local 
or distant recurrence.  
The one year overall survival in our study was 97% which is similar to that of Shina et al., 
2005 (23) but less than Lencioni et al., 2003(24) which was 100%. 
However our results are higher than those of Lin et al., 2004 (25) and Lin et al., 2005 (26) (90% , 
93% respectively ). At the end of the study (1 year ) ,15 patients (18.9% ) lived with either 
local recurrence or denovo lesion. Lin et al., 2003 reported 18%  local recurrence at the end 
of their study (2 year )  while over the same period Lncioni et al ., 2003 reported only 4%  
local recurrence and no report on denovo lesions.  
In this series nearly all the patients experienced post-ablation minor complication as right 
hypochondrial pain that was controlled by analgesics and nausea, which was controlled by 
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antiemetics Also, nearly all experienced post – ablation pyrexia for 1-3 days, which was 
controlled by antipyretics it agrees with Mulier et al., 2002 (27) reported 93% of HCC patients 
in his study experienced post-ablation right hypochondrial pain. 
 Many authors have regarded low grade fever, mild right upper quadrant pain, small 
asymptomatic pleural effusions and transient elevation of liver functions following hepatic 
RFA. In reports reviewed, other minor complications included intra or peri hepatic abscess, 
minor hemorrhage, ascites, myoglobinuria and thrombocytopenia (28). In the early studies of 
hepatic RFA, full thickness skin burns at the grounding pad sites were noted rarely and it 
was considered a major complication.  
Another complication which deserves discussion is percutaneus ablation needle track 
tumour seeding but both these complications were not met in the present study. 
Only one patient developed pneumothorax due to ablation of Sub-diaphragmatic tumour 
and another 2 patients developed ascites within the first week post ablation.   
Conclusion: Radiofrequency thermal ablation is a technology that can be applied to 
unresectable hepatic tumours without significant morbidity when patients and treatment 
approach are chosen carefully.                                                                                                  
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